Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.

Vilgelm AE, Saleh N, Shattuck-Brandt R, Riemenschneider K, Slesur L, Chen SC, Johnson CA, Yang J, Blevins A, Yan C, Johnson DB, Al-Rohil RN, Halilovic E, Kauffmann RM, Kelley M, Ayers GD, Richmond A.

Sci Transl Med. 2019 Aug 14;11(505). pii: eaav7171. doi: 10.1126/scitranslmed.aav7171.

PMID:
31413145
2.

Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.

Vilgelm AE, Richmond A.

Front Immunol. 2019 Feb 27;10:333. doi: 10.3389/fimmu.2019.00333. eCollection 2019. Review.

3.

Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms.

Yang J, Kumar A, Vilgelm AE, Chen SC, Ayers GD, Novitskiy SV, Joyce S, Richmond A.

Cancer Immunol Res. 2018 Oct;6(10):1186-1198. doi: 10.1158/2326-6066.CIR-18-0045. Epub 2018 Aug 14.

4.

MDM2 Antagonists Counteract Drug-Induced DNA Damage.

Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A.

EBioMedicine. 2017 Oct;24:43-55. doi: 10.1016/j.ebiom.2017.09.016. Epub 2017 Sep 19.

5.

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A.

Clin Cancer Res. 2017 Jul 1;23(13):3371-3384. doi: 10.1158/1078-0432.CCR-16-2142. Epub 2016 Dec 21. Erratum in: Clin Cancer Res. 2018 Aug 1;24(15):3782.

6.

Combinatorial approach to cancer immunotherapy: strength in numbers.

Vilgelm AE, Johnson DB, Richmond A.

J Leukoc Biol. 2016 Aug;100(2):275-90. doi: 10.1189/jlb.5RI0116-013RR. Epub 2016 Jun 2. Review.

7.

Using avatars to win the fight over BRAF inhibitor resistance.

Vilgelm AE, Richmond A.

Pigment Cell Melanoma Res. 2016 Jul;29(4):398-9. doi: 10.1111/pcmr.12473. Epub 2016 May 17. No abstract available.

8.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.

Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM.

Nat Commun. 2016 Jan 29;7:10582. doi: 10.1038/ncomms10582.

9.

Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.

Vilgelm AE, Johnson CA, Prasad N, Yang J, Chen SC, Ayers GD, Pawlikowski JS, Raman D, Sosman JA, Kelley M, Ecsedy JA, Shyr Y, Levy SE, Richmond A.

J Natl Cancer Inst. 2015 Dec 30;108(6):djv406. doi: 10.1093/jnci/djv406. Print 2016 Jun.

10.

Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses.

Vilgelm A, Richmond A.

Oncoimmunology. 2015 Mar 19;4(8):e1009299. eCollection 2015 Aug.

11.

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.

Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A.

Clin Cancer Res. 2015 Dec 1;21(23):5338-48. doi: 10.1158/1078-0432.CCR-15-0293. Epub 2015 Jul 7.

12.

Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart CF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN, Richmond A.

Cancer Res. 2015 Jan 1;75(1):181-93. doi: 10.1158/0008-5472.CAN-14-2405. Epub 2014 Nov 14.

13.

Engineered three-dimensional microfluidic device for interrogating cell-cell interactions in the tumor microenvironment.

Hockemeyer K, Janetopoulos C, Terekhov A, Hofmeister W, Vilgelm A, Costa L, Wikswo JP, Richmond A.

Biomicrofluidics. 2014 Jul 15;8(4):044105. doi: 10.1063/1.4890330. eCollection 2014 Jul.

14.

Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale.

Davis TA, Vilgelm AE, Richmond A, Johnston JN.

J Org Chem. 2013 Nov 1;78(21):10605-16. doi: 10.1021/jo401321a. Epub 2013 Oct 15.

15.

Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.

Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A.

EMBO Mol Med. 2013 Jan;5(1):149-66. doi: 10.1002/emmm.201201378. Epub 2012 Nov 25.

16.

RAF265 inhibits the growth of advanced human melanoma tumors.

Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A.

Clin Cancer Res. 2012 Apr 15;18(8):2184-98. doi: 10.1158/1078-0432.CCR-11-1122. Epub 2012 Feb 20. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475.

17.

[The coordinated interaction of multifunctional members of p53 family determines many key processes in multicellular organisms].

Vilgelm AE, Zaika AI, Prasolov VS.

Mol Biol (Mosk). 2011 Jan-Feb;45(1):180-97. Review. Russian.

PMID:
21485507
18.

Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors.

Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W, Zaika A.

Oncogene. 2010 Oct 28;29(43):5861-8. doi: 10.1038/onc.2010.319. Epub 2010 Aug 2.

19.

Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells.

Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, Piazuelo MB, Correa P, Washington MK, El-Rifai W, Peek RM, Zaika A.

Gastroenterology. 2010 Oct;139(4):1333-43. doi: 10.1053/j.gastro.2010.06.018. Epub 2010 Jun 12.

20.

Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors.

Vilgelm AE, Washington MK, Wei J, Chen H, Prassolov VS, Zaika AI.

Mol Cancer Ther. 2010 Mar;9(3):693-705. doi: 10.1158/1535-7163.MCT-09-0912. Epub 2010 Mar 2.

21.

Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Vilgelm A, El-Rifai W, Zaika A.

Drug Resist Updat. 2008 Aug-Oct;11(4-5):152-63. doi: 10.1016/j.drup.2008.08.001. Epub 2008 Sep 17. Review.

22.

Interaction of Helicobacter pylori with gastric epithelial cells is mediated by the p53 protein family.

Wei J, O'Brien D, Vilgelm A, Piazuelo MB, Correa P, Washington MK, El-Rifai W, Peek RM, Zaika A.

Gastroenterology. 2008 May;134(5):1412-23. doi: 10.1053/j.gastro.2008.01.072. Epub 2008 Jan 31.

23.

DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function.

Vilgelm A, Wei JX, Piazuelo MB, Washington MK, Prassolov V, El-Rifai W, Zaika A.

Oncogene. 2008 Apr 3;27(15):2170-6. Epub 2007 Oct 22.

24.

The gastrin gene promoter is regulated by p73 isoforms in tumor cells.

Tomkova K, El-Rifai W, Vilgelm A, Kelly MC, Wang TC, Zaika AI.

Oncogene. 2006 Sep 28;25(44):6032-6. Epub 2006 Apr 24.

PMID:
16636659
25.

Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice.

Vilgelm A, Lian Z, Wang H, Beauparlant SL, Klein-Szanto A, Ellenson LH, Di Cristofano A.

Cancer Res. 2006 Apr 1;66(7):3375-80.

Supplemental Content

Loading ...
Support Center